EP3946595
Stillimiðlar fyrir gegnumhimnuleiðni í slímseigjusjúkdómi
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
2.4.2020EP published:
15.11.2023EP application number:
20722087.2
EP translation filed:
11.12.2023Grant published:
15.1.2024EPO information:
European Patent Register
Max expiry date:
1.4.2040Expiry date:
1.4.2026Next due date:
30.4.2026
Title in English:
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTSLanguage of the patent:
English
Timeline
Today
2.4.2020EP application
15.11.2023EP Publication
11.12.2023Translation submitted
15.1.2024Registration published
1.4.2026Expires
Owner
Name:
Vertex Pharmaceuticals IncorporatedAddress:
50 Northern Avenue, Boston, MA 02210, US
Inventor
Name:
HADIDA RUAH, Sara SabinaAddress:
Boston, Massachusetts 02210, US
Name:
ISHIHARA, YoshihiroAddress:
Boston, Massachusetts 02210, US
Name:
KRENITSKY, PaulAddress:
Boston, Massachusetts 02210, US
Name:
MCCARTNEY, JasonAddress:
Boston, Massachusetts 02210, US
Name:
MELILLO, VitoAddress:
Boston, Massachusetts 02210, US
Name:
MILLER, Mark ThomasAddress:
Boston, Massachusetts 02210, US
Name:
SILINA, AlinaAddress:
Boston, Massachusetts 02210, US
Name:
UY, JohnnyAddress:
Boston, Massachusetts 02210, US
Name:
ZHOU, JinglanAddress:
Boston, Massachusetts 02210, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201962828699 PDate:
3.4.2019Country:
US
Classification
Categories:
A61P 11/00, C07D 239/69, C07D 515/08
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 7.3.2024
Expires: 1.4.2025
Payer: Árnason Faktor ehf.
Number: 6
Paid: 2.4.2025
Expires: 1.4.2026
Payer: Árnason Faktor ehf.